Read More

Entera Bio Shares Spike Higher Following Co. Press Release Highlighting Upcoming Jun. 30 Conference Call To Discuss ‘Phase 2 Results for EB613 Positioned to be the First Oral Bone-Building Agent for the Treatment of Osteoporosis’

Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced it will conduct a conference call to discuss results from its successfully completed Phase 2

ENTX